BrainStorm Cell Therapeutics Inc.(OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it received a visit yesterday by the Israeli Minister of Science and Technology, Professor Daniel Hershkowitz. The purpose of the visit was to review BrainStorm’s progress towards the start of its first clinical trials in ALS. Professor Hershkowitz met with BrainStorm’s management and scientific team during his visit and received a detailed presentation of the Company’s science from Professor Eldad Melamed, BrainStorm’s Chief Medical Advisor and Professor Daniel Offen, BrainStorm’s Chief Scientist.
“We are extremely pleased with the visit by Professor Hershkowitz”
“We are extremely pleased with the visit by Professor Hershkowitz,” stated Rami Efrati, CEO of BrainStorm. “This is the first visit by Israeli Ministry of Science and Technology and we look forward to building a strong and lasting relationship with them. The visit by Professor Hershkowitz signals the importance of the work we are doing at BrainStorm as we prepare to begin our clinical trials in ALS this year.”
Duke-NUS team develops test to monitor engineered T cells in cancer treatment